The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | Toxicity of beti-cel in transfusion-dependent β-thalassemia
Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, discusses the side effects induced by treatment with betibeglogene autotemcel (beti-cel) in patients with transfusion-dependent β-thalassemia. Data has shown that beti-cel may impact fertility, and it is therefore important to conduct fertility management prior to treatment. A further follow-up is required to evaluate the potential of insertional mutagenesis and induction of leukemia. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
